Bis-S-acyl-2-thioethyl (SATE)-bearing monophosphate prodrug of beta-L-FD4C as potent anti-HBV agent.
The S-acyl-2-thioethyl (SATE)-bearing 5'-monophosphate prodrug of beta-L-FD4C (8) was synthesized and evaluated for its activity against HBV in the 2.2.15 cell line. This pronucleotide (8) exhibited an excellent inhibitory effect against HBV with an EC50 value that is more than eight fold lower than that of the parent nucleoside (4) under some assay conditions. It is also important to note that pronucleotide (8) was capable of inhibiting HBV replication by 90%; whereas its parent, beta-L-FD4C (4), could only inhibit virus replication no greater than 70% in the same assay. When evaluated in the standard cytotoxicity assay in CEM cell line, pronucleotide (8) exhibited an IC50 value of 52 microM, which was four times less toxic than parent beta-L-FD4C (4) (IC50 = 13 microM).
Li
X
X
Vion Pharmaceuticals, Inc., New Haven, CT 06511, USA.
Carmichael
E
E
Feng
M
M
King
I
I
Doyle
T W
TW
Chen
S H
SH
D000998:Antiviral Agents / Q000737:chemistry / Q000494:pharmacology*; D002470:Cell Survival / Q000187:drug effects; D006515:Hepatitis B virus / Q000187:drug effects*; D006801:Humans; D009943:Organophosphorus Compounds / Q000737:chemistry*; D011355:Prodrugs / Q000737:chemistry / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D016047:Zalcitabine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology
D000998:Antiviral Agents; D009943:Organophosphorus Compounds; D011355:Prodrugs; D016047:Zalcitabine; C099405:dexelvucitabine